scholarly journals Determination of Epstein-Barr virus (EBV) incidence in umbilical cord blood (UCB) and assessment of virus DNA via Real-time PCR

2021 ◽  
Vol 29 (1) ◽  
pp. 114-120
Author(s):  
Afsaneh Jahangiryan ◽  
Maryam Kheirandish ◽  
Shahram Samiee ◽  
Zohreh Sharifi ◽  
Mastaneh Alaei
Keyword(s):  
Cord Blood ◽  
Real Time ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Real Time Pcr ◽  
Epstein Barr Virus ◽  
Barr Virus ◽  
Epstein Barr

CD4+ Epstein–Barr Virus-Specific Cytotoxic T-Lymphocytes from Human Umbilical Cord Blood

1999 ◽  
Vol 195 (2) ◽  
pp. 81-88 ◽  
Author(s):  
Qi Sun ◽  
Robert L. Burton ◽  
Karen E. Pollok ◽  
David J. Emanuel ◽  
Kenneth G. Lucas
Keyword(s):  
T Lymphocytes ◽  
Cord Blood ◽  
Umbilical Cord ◽  
Cytotoxic T Lymphocytes ◽  
Umbilical Cord Blood ◽  
Epstein Barr Virus ◽  
Human Umbilical Cord Blood ◽  
Human Umbilical Cord ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation

Blood ◽  
2006 ◽  
Vol 108 (8) ◽  
pp. 2874-2880 ◽  
Author(s):  
Claudio G. Brunstein ◽  
Daniel J. Weisdorf ◽  
Todd DeFor ◽  
Juliet N. Barker ◽  
Jakub Tolar ◽  
...  
Keyword(s):  
Cord Blood ◽  
Umbilical Cord ◽  
Umbilical Cord Blood ◽  
Antithymocyte Globulin ◽  
Epstein Barr Virus ◽  
Close Monitoring ◽  
Barr Virus ◽  
Increased Risk ◽  
Preparative Regimen ◽  
Epstein Barr

AbstractUmbilical cord blood (UCB) is increasingly used as an alternative source of hematopoietic stem cells for transplantation for patients who lack a suitable sibling donor. Despite concerns about a possible increased risk of Epstein-Barr virus (EBV) posttransplantation lymphoproliferative disorder (PTLD) after UCB transplantation, early reports documented rates of PTLD comparable to those reported after HLA-matched unrelated marrow myeloablative (MA) transplantations. To further investigate the incidence of EBV PTLD after UCB transplantation and potential risk factors, we evaluated the incidence of EBV-related complications in 335 patients undergoing UCB transplantation with an MA or nonmyeloablative (NMA) preparative regimen. The incidence of EBV-related complications was a 4.5% overall, 3.3% for MA transplantations, and 7% for NMA transplantations. However, the incidence of EBV-related complications was significantly higher in a subset of patients treated with an NMA preparative regimen that included antithymocyte globulin (ATG) versus those that did not (21% vs 2%; P < .01). Nine of 11 patients who developed EBV PTLD were treated with rituximab (anti-CD20 antibody), with the 5 responders being alive and disease free at a median of 26 months. Use of ATG in recipients of an NMA preparative regimen warrants close monitoring for evidence of EBV reactivation and potentially preemptive therapy with rituximab.

Sign in / Sign up

Export Citation Format

Share Document